ABOUT
Team
Our Management Team
Rosamond Deegan Chief Executive Officer Read More
Rosamond Deegan
Chief Executive Officer
Ros Deegan joined OMass Therapeutics as CEO in May 2019 from Bicycle Therapeutics where she served as President, Chief Business Officer and a Director of the US subsidiary of the Company. Ros established the company’s Boston-based subsidiary and over a three-year period led three major transactions and grew the US organisation to more than 20 employees. Prior to that Ros served as Senior Vice President, Business Development and Operations at Trevena, Inc, where she had previously held the role of Head of Finance and Operations. During Ros’ tenure at Bicycle and Trevena, the companies moved four programmes into the clinic, and raised over $300 million in private and public financings. In her earlier career, Ros was Director of Business Development at GSK in the US and, prior to that, she served as Director of Operations for GSK’s Centre of Excellence for External Drug Discovery (CEED) and as Marketing Manager for GSK’s UK launch of Bonviva for post-menopausal osteoporosis. Ros is a graduate of Cambridge University and received her MBA with distinction from INSEAD.
Dr Ali Jazayeri Chief Scientific Officer Read More
Dr Ali Jazayeri
Chief Scientific Officer
Ali Jazayeri joined OMass Therapeutics in October 2018. He was previously Chief Technology Officer of Heptares Therapeutics, a company he joined in 2007 as one of the first scientists and was involved in the transfer of the GPCR stabilisation technology from the MRC Laboratory of Molecular Biology to Heptares. Following successful implementation and industrialisation of the original technology, he led the development of novel methodologies that significantly increased the efficiency and reach of the technology and resulted in the generation of novel IP. In addition, he was one of the key members of the executive sub-team that lead the acquisition of G7 therapeutics, spin out company from University of Zurich and went on to lead the further development and integration of their technology as part of the Heptares Zurich management team. Prior to Heptares, Ali worked as a post-doctoral scientist in Clare Hall Laboratories (a Cancer Research UK institute) and Kudos Pharmaceuticals (later acquired by AstraZeneca) where he carried out research on the role of cell cycle checkpoint kinases in DNA damage response pathways. He has a BSc in Genetics from University of Manchester and obtained his PhD in molecular biology with Prof Steve Jackson at the Gurdon Institute from University of Cambridge.
Dr Jonathan Hopper Vice President, Platforms and Founder Read More
Dr Jonathan Hopper
Vice President, Platforms and Founder
Jonathan Hopper is Vice President, Platforms and founder of OMass Therapeutics. Jonathan completed his PhD in native mass spectrometry under the supervision of Prof. Neil Oldham and moved to the University of Oxford to develop native mass spectrometry approaches for studying membrane proteins with Professor Dame Carol Robinson. His research was focussed on developing technologies which enable or improve the structural/functional information obtained on challenging membrane protein assemblies and drug targets. He founded OMass and served as the first Chief Executive Officer, leading the company through its seed funding and series A financing rounds, allowing OMass to develop its own drug discovery programmes in-house.
Dr Hsin Loke Vice President, Finance & Operations Read More
Dr Hsin Loke
Vice President, Finance & Operations
Hsin Loke joined OMass Therapeutics in July 2018 as Vice President, Head of Finance and Strategy. Previously she spent 16 years at GSK in a variety of leadership roles; most recently leading Finance, Strategy and Operations for the Company’s Rare Diseases Unit, which developed and commercialised a portfolio of innovative medicines, including gene therapies. Prior to this, Hsin led Strategy and Operations for GSK’s biopharm unit, and has held roles within an internal consulting group, commercial finance and internal audit. Hsin qualified as a Chartered Accountant with PwC, and completed her BA (Hons) in Biological Sciences and D.Phil. in genetics and immunology at Oxford University.
Dr Giles Brown Vice President, Medicinal Chemistry Read More
Dr Giles Brown
Vice President, Medicinal Chemistry
Giles Brown joined OMass Therapeutics as Vice President, Medicinal Chemistry in October 2018 from Heptares Therapeutics. He joined Heptares in 2010 to help develop their structural biology platform as a new approach to structure-based drug design and lead identification for GPCRs. He was promoted to Director of Chemistry in 2015 and Head of Medicinal Chemistry in early 2018. Prior to that he worked for Cambridge BioTechnology (which was acquired by BioVitrum in 2005) as a Medicinal Chemistry Team Leader to help establish the chemistry team and advance the internal pipeline. Previously he worked for Evotec OAI, as a Senior Scientist, a role he took on after completing a two-year postdoctoral position at the University of Pennsylvania in synthetic chemistry. Giles obtained a BSc and PhD in organic chemistry from the University of Bristol and an MBA from Henley Business School at the University of Reading, he is a Fellow of the Royal Society of Chemistry.
Professor Steven Charlton Vice President, Pharmacology Read More
Professor Steven Charlton
Vice President, Pharmacology
Steven Charlton joined OMass Therapeutics as Vice President, Pharmacology in February 2020. Prior to that he was co-founder and CSO at Excellerate Bioscience, a CRO providing specialist molecular pharmacology support to the pharmaceutical industry. Steven has over 20 years drug discovery experience, with previous roles at both SmithKline Beecham and Novartis. At Novartis he was Director of Molecular Pharmacology in Respiratory Diseases, leading an assay development and compound profiling team of over 30 scientists providing expert opinion and support for many GPCR and other membrane protein targets. He also served on development teams covering late clinical development through post-launch. In 2007 Steven was awarded Novartis Leading Scientist in recognition of his contribution to the field of quantitative pharmacology and to the Novartis pipeline. Steven is also Professor of Molecular Pharmacology and Drug Discovery in the School of Life Sciences at Nottingham University, and a Fellow of the British Pharmacological Society.
Our Board Of Directors
Rosamond Deegan Chief Executive Officer Read More
Rosamond Deegan
Chief Executive Officer
Ros Deegan joined OMass Therapeutics as CEO in May 2019 from Bicycle Therapeutics where she served as President, Chief Business Officer and a Director of the US subsidiary of the Company. Ros established the company’s Boston-based subsidiary and over a three-year period led three major transactions and grew the US organisation to more than 20 employees. Prior to that Ros served as Senior Vice President, Business Development and Operations at Trevena, Inc, where she had previously held the role of Head of Finance and Operations. During Ros’ tenure at Bicycle and Trevena, the companies moved four programmes into the clinic, and raised over $300 million in private and public financings. In her earlier career, Ros was Director of Business Development at GSK in the US and, prior to that, she served as Director of Operations for GSK’s Centre of Excellence for External Drug Discovery (CEED) and as Marketing Manager for GSK’s UK launch of Bonviva for post-menopausal osteoporosis. Ros is a graduate of Cambridge University and received her MBA with distinction from INSEAD.
Dr Edward Hodgkin Chairman Read More
Dr Edward Hodgkin
Chairman
Edward Hodgkin is Chairman of OMass Therapeutics. He is a Partner at Syncona Investment Management Ltd. and was previously a Director of Syncona’s portfolio company, Autolus Therapeutics Ltd. (NASDAQ: AUTL); having served as its first Chief Executive Officer. Prior to Syncona, Ed was Chief Executive Officer of Biotica Technology Ltd. (Cambridge, UK), President & Chief Business Officer of BrainCells Inc. (San Diego, CA) and Vice President, Business Development & Marketing at Tripos (St. Louis, MO). He is also a former chairman of the BioIndustry Association, the UK’s trade body for biotechnology companies. Ed holds an MA and DPhil in Chemistry from the University of Oxford.
Professor Dame Carol Robinson Founder and Scientific Advisor Read More
Professor Dame Carol Robinson
Founder and Scientific Advisor
Carol is founder of OMass Therapeutics and is a is a non-executive Director and an advisor to the Company. She was appointed Dame Commander of the Order of the British Empire (DBE) in the 2013 New Year Honours for services to science and industry. She is recognised for using mass spectrometry to further research into the 3D structure of proteins and their complexes. Carol’s graduate education was completed whilst working full-time in industry. In 2001 she became the first female Professor in Chemistry at the University of Cambridge, and in 2009 went to the University of Oxford to become the Chair of Dr. Lee’s Professor of Chemistry; a title she still holds. She also holds eight honorary doctorates/degrees, was elected as a Foreign Associate of the US National Academy of Sciences in 2017 and she is the current President of the Royal Society of Chemistry.
Dr Magdalena Jonikas Non-executive Director Read More
Dr Magdalena Jonikas
Non-executive Director
Magdalena is a non-executive Director of OMass Therapeutics. She is a partner of Syncona Investment Management Ltd and previously was an Associate Partner at McKinsey & Company where she specialised in pharmaceuticals Research & Development, portfolio management and Business Development and Licensing. Magdalena holds a PhD in Bioengineering from Stanford University and was a postdoctoral fellow in Harvard Medical School’s Computational Health Informatics Programme.
Chris Ashton Non-executive Director Read More
Chris Ashton
Non-executive Director
Chris is a non-executive Director of OMass Therapeutics. He has been an advisor to Oxford Science Enterprises since December 2019 and serves as Chairman of the Board of PepGen. He is a seasoned biotech entrepreneur with over 35 years’ experience in the biotechnology industry. Chris has considerable expertise in leading and growing early stage companies and enabling their transition to mid-stage clinical development organisations. He has extensive international transactional experience in both listed and private companies including fund raising, licensing and M&A activity. Chris was formerly a Partner at Syncona, a FTSE 250 company, where he was also founding CEO of Achilles Therapeutics. Prior to that he was CEO of Argenta Discovery (sold to Galapagos) and Pulmagen Therapeutics. Chris has a PhD from the University of Manchester (UMIST) and carried out post-doctoral research at the Massachusetts Institute of Technology (MIT).
Jonathan Montagu Non-executive Director Read More
Jonathan Montagu
Non-executive Director
Jonathan is a non-executive Director of OMass Therapeutics. He is the Co-Founder and Chief Executive Officer of HotSpot Therapeutics, a company targeting nature’s regulatory mechanisms to create high precision allosteric medicines for the treatment of serious autoimmune and metabolic diseases. Prior to co-founding HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics, where he helped establish the company’s drug discovery platform and pipeline. He also served as Vice President, Business Development at Concert Pharmaceuticals, and was instrumental in securing a $1B multi-product transaction for the company with GSK. Jonathan trained as a chemist at Oxford University, Cold Spring Harbor Laboratory, The Scripps Research Institute, and Cancer Research UK.
Dr Nathalie Franchimont Non-executive Director Read More
Dr Nathalie Franchimont
Non-executive Director
Nathalie Franchimont is a non-executive Director of OMass Therapeutics. She currently serves as Senior Vice President, Head of Multiple Sclerosis (MS) and Immunology Development Unit at Biogen and is a member of the R&D Leadership Team. Her extensive career in large biotechnology companies (Amgen and Biogen) has spanned drug development from discovery research and target validation through early and late clinical development including multiple filings globally, medical affairs with launch and reimbursement in the international markets. Nathalie is a rheumatologist and trained as an M.D., Ph.D. at the University of Liège, Belgium. She has held research fellowship roles at the University of Connecticut School of Medicine/Saint Francis Hospital (Bone Biology), Yale University School of Medicine (Rheumatology) and University of Liège where she worked as Chief of Clinic and Research Associate (FNRS) in Rheumatology.
Dr Martin Murphy Observer Read More
Dr Martin Murphy
Observer
Martin Murphy is Chief Executive Officer of Syncona Investment Management Ltd and was co-founder of Syncona. Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations and was closely involved in investments including PregLem SA, Momenta Pharmaceuticals, Inc, Healthcare Brands International and Heptares Therapeutics Ltd. Martin has held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.
Steve Silvey Observer Read More
Steve Silvey
Observer
Steve is a Senior Investment Manager at Oxford University Innovation (OUI). OUI is the commercialisation arm of the University of Oxford, working with researchers, investors, entrepreneurs, corporations, and clinicians to foster a world leading innovation ecosystem with Oxford University at its heart. He manages the University’s equity interests in its life sciences portfolio, covering a broad range of disciplines including drug development, med-tech, diagnostics, and digital health. This includes investing on behalf of the University in follow on rounds for selected spin outs. Steve joined OUI in 2018 from an ASX listed IP investment firm specialising in university spin out creation and has more than 20 years of governance, executive and investing experience in early stage and high growth companies. He studied biology, has an MBA and is a Chartered Accountant.
Founders Of The Company
Professor Dame Carol Robinson Founder and Scientific Advisor Read More
Professor Dame Carol Robinson
Founder and Scientific Advisor
Carol is founder of OMass Therapeutics and is a is a non-executive Director and an advisor to the Company. She was appointed Dame Commander of the Order of the British Empire (DBE) in the 2013 New Year Honours for services to science and industry. She is recognised for using mass spectrometry to further research into the 3D structure of proteins and their complexes. Carol’s graduate education was completed whilst working full-time in industry. In 2001 she became the first female Professor in Chemistry at the University of Cambridge, and in 2009 went to the University of Oxford to become the Chair of Dr. Lee’s Professor of Chemistry; a title she still holds. She also holds eight honorary doctorates/degrees, was elected as a Foreign Associate of the US National Academy of Sciences in 2017 and she is the current President of the Royal Society of Chemistry.
Dr Idlir Liko Director of Technology and Founder Read More
Dr Idlir Liko
Director of Technology and Founder
Idlir Liko is the Technology Director and founder of OMass Therapeutics. He received a Master’s Degree from ETH Zurich in 2012 and DPhil from the University of Oxford in 2015, supervised by Prof. Dame Carol Robinson where he focused on the effect ligands and PTMs have on structure and stability of membrane proteins. His work was been featured in many high-impact publications. He has a wealth of experience in structural MS working in close collaboration with biotech and pharmaceutical companies. In 2016, he co-founded the company and has played a key role in transferring our technology from academia to industry.
Dr Jonathan Hopper Vice President, Platforms and Founder Read More
Dr Jonathan Hopper
Vice President, Platforms and Founder
Jonathan Hopper is Vice President, Platforms and founder of OMass Therapeutics. Jonathan completed his PhD in native mass spectrometry under the supervision of Prof. Neil Oldham and moved to the University of Oxford to develop native mass spectrometry approaches for studying membrane proteins with Professor Dame Carol Robinson. His research was focussed on developing technologies which enable or improve the structural/functional information obtained on challenging membrane protein assemblies and drug targets. He founded OMass and served as the first Chief Executive Officer, leading the company through its seed funding and series A financing rounds, allowing OMass to develop its own drug discovery programmes in-house.
Dr Hsin Yung (Jason) Yen Director of Biology and Founder Read More
Dr Hsin Yung (Jason) Yen
Director of Biology and Founder
Hsin-Yung (Jason) Yen is the Director of Biology and founder of OMass Therapeutics. After obtaining his PhD degree in glycobiology with Prof Chi-Huey Wong he became a post-doctoral scientist in Professor Dame Carol Robinson’s research group at the University of Oxford. Following his success in GPCR analysis with state-of-the-art mass spectrometry, he recorded the first mass spectrum of a folded GPCR with drug binding maintained. He invented a mass spectrometry platform that reports on compound efficacy on G proteins-/arrestins – coupling with receptors. Now he is leading the scientific team dedicated to GPCR drug discovery.

WORKING HERE

Together we are discovering new drugs to treat orphan or immunological disease

We are headquartered in Oxford, UK with additional laboratories in Nottingham. We are well-financed and backed by a top-tier investor syndicate. Find out more about life at OMass and current vacancies

Join Us